Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

22 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Health Protection Agency Articles

Novartis sells rights to Proleukin in the USA to Prometheus; gets license for vaccine from IIG; and pleads guilty over Trileptal

27 January 2010

ECDC expresses concern on antibiotics overuse; will warn doctors

11 November 2009

UK vaccine coverage drop leads to measles outbreaks

15 January 2009

Lipoxen enters accord to eliminate "cold chain"

20 October 2008

More antibiotic development needed, warns UK's HPA

22 September 2008

Strong Ph II data for Novartis' MenB vacc

26 May 2008

UK govt claims 300 children saved by vacc

7 January 2008

Raised hep C awareness lead to 10% rise in England diagnosis

24 December 2007

Study shows benefits of HPV 6 and 11 vacc

15 October 2007

Nabi initiates first European StaphVAX trial in UK

23 May 2005

Showing 1-10 of 10 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Is failure to adopt business process management putting the pharma industry at risk?
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Is failure to adopt business process management putting the pharma industry at risk?
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS